Trials / Unknown
UnknownNCT04955171
BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema
Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Diabetic Macular Edema
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Diabetic macular edema degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management
Detailed description
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab(BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea;Regeneron, Tarrytown,NY)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BEOVU intravitreal injection | BEOVU intravitreal injection |
Timeline
- Start date
- 2021-01-12
- Primary completion
- 2022-03-01
- Completion
- 2022-04-01
- First posted
- 2021-07-08
- Last updated
- 2021-07-08
Locations
1 site across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT04955171. Inclusion in this directory is not an endorsement.